Germantown, Maryland, Dec. 26, 2011 – Avanti Therapeutics, Inc., an innovative biopharmaceutical company engaged in the development of personalized healthcare products for the treatment of cancer announced the commencement of the initial development of its Aayush- platform technology for a novel class of therapeutics for personalized treatment of Ovarian and other cancers based on multifunctional nanoparticles.
Dr. Arkesh Mehta, the Company’s Chairman and CEO and inventor of the NanoBindi technology, provided a brief description of the Aayush technology during his presentation at French Biotech Tour 2011 at the MIT Faculty Club, in Cambridge, Massachusetts.
The innovative multifunctional nanoparticle - based technology has the potential to improve on current methods of chemotherapy by increasing efficacy of paclitaxel, reducing the side effects and by delivering potent cytotoxic molecules to sites of cancer. NanoBindis are designed to reduce side effects caused by chemotherapy agents while delivering the paclitaxel to the targeted cancer cells. The company’s lead candidate is AT-KT-124-T, encapsulated paclitaxel- biodegradable multi-functional nanoparticles with core shell architecture, stabilized humanized antibody specific for ovarian cancer cells.
“We believe this exciting new approach may herald a new generation of promising drug candidates for the treatment of currently untreatable life-threatening diseases. Multi-functional nanoparticle based Aayush platform capitalizes on the tremendous advances already made in the area of nanoparticles for cancer which have generated a plethora of advanced enabling drug conjugation technologies and also uses independent approaches,” said Arkesh Mehta, Ph.D., Chairman and CEO of Avanti Therapeutics and inventor of the Aayush Platform technology.
“While multi-functional nanoparticle technology is still at the earliest stage of development and requires substantial work before new drug candidates can be tested in human clinical trials, we are very optimistic regarding its potential, and look forward to reporting our progress as soon as possible.”
Avanti’s new platform may also have applications for in vivo imaging of clinical biomarkers for cancer, which may be useful for diagnosis of disease and monitoring of drug effectiveness. The Company has applied for a patent for its NanoBindi technology.
About Avanti Therapeutics:
Avanti Therapeutics develops innovative personalized healthcare products using its Aayush™ technology platform. Aayush™ personalized products platform utilizes proprietary multifunctional nanoparticles with a core-shell architecture. Products developed incorporating The Aayush™ platform provide distinct competitive advantages in terms of enhancing the clinical utility as well as product life cycles in a cost efficient manner. Avanti has completed number of proof of concept studies for products in oncology, cardiovascular diseases, neurodegenerative diseases, vaccines and regenerative medicine. The company is seeking out-licensing partners to bring its re-purposed product pipelines to market. Avanti has number of short runway re-purposed product candidates with completed animal proof of concept studies, available for developmental commercialization.
For more information please visit www.AT-GC.com
Contact:
Jenny Smith
Avanti Therapeutics
jenny@at-gc.com
202-677-5426
